

**A: Originalarbeiten als Erst- oder Letztautor**

1. **How Octogenarians with Bladder Cancer Are Treated in a Maximum-Care Hospital: The Real-Life Experience.**  
Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Lieb V, Krause FS, Merten R, Ott O, Fietkau R, Wullich B, Keck B.  
**Urol Int. 2017;98(3):262-267.**
2. **Female Gender Is an Age-dependent Negative Prognostic Factor for Patients with Upper Tract Urothelial Carcinoma.**  
Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Goebell PJ, Schick S, Olbert P, Huber J, Wullich B, Keck B.  
**Anticancer Res. 2015 Jul;35(7):4277-81**
3. **Comparative genomic hybridization shows complex genomic changes of plasmacytoid urothelial carcinoma.**  
Keck B, Ellmann C, Stoehr R, Weigelt K, Goebell PJ, Kunath F, Taubert H, Hartmann A, Wullich B, Wach S.  
**Urol Oncol. 2014 Nov;32(8):1234-9.**
4. **Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients.**  
Keck B, Wach S, Taubert H, Zeiler S, Ott OJ, Kunath F, Hartmann A, Bertz S, Weiss C, Hönscheid P, Schellenburg S, Rödel C, Baretton GB, Sauer R, Fietkau R, Wullich B, Krause FS, Datta K, Muders MH.  
**Int J Cancer. 2015 Jan 15;136(2):443-51**
5. **Bladder cancer -- the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.gov.**  
Kunath F, Krause SF, Wullich B, Goebell PJ, Engehausen DG, Burger M, Meerpohl JJ, Keck B.  
**BMC Urol. 2013 24;13(1):56.**
6. **SNAI1 Protein Expression is an Independent Negative Prognosticator in Muscle-Invasive Bladder Cancer.**

**Keck B, Wach S, Goebell PJ, Kunath F, Bertz S, Lehmann J, Stöckle M, Taubert H, Wullich B, Hartmann A.**

**Ann Surg Oncol. 2013;20(11):3669-74.**

**7. Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy**

**Bastian Keck, Sven Wach, Robert Stoehr, Frank Kunath, Simone Bertz, Jan Lehmann, Michael Stöckle, Helge Taubert, Bernd Wullich, Arndt Hartmann**

**BMC Cancer. 2013 8;13:71.**

**8. Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder**

**Bastian Keck, Sven Wach, Frank Kunath, Simone Bertz, Helge Taubert, Jan Lehmann, Michael Stöckle, Bernd Wullich, Arndt Hartmann**

**Ann Surg Oncol. 2013;20(7):2440-5.**

**9. Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy**

**Bastian Keck, Oliver J. Ott, Lothar Häberle, Frank Kunath, Christian Weiss, Claus Rödel, Rolf Sauer, Rainer Fietkau, Bernd Wullich, Frens S. Krause**

**World J Urol. 2013;31(5):1023-8.**

**10. The plasmacytoid carcinoma of the bladder – rare variant of aggressive urothelial carcinoma**

**Bastian Keck, Robert Stoehr, Sven Wach, Anja Rogler, Ferdinand Hofstaedter, Jan Lehmann, Rodolfo Montironi, Mathilde Sibonye, Hans M Fritsche, Antonio Lopez-Beltran, Jonathan I. Epstein, Bernd Wullich and Arndt Hartmann**

**Int J Cancer. 2010;15;129(2):346-54.**

## **11. Das Plasmacytoide und Mikropapilläre Urothelkarzinom als seltene Varianten eines Urothelkarzinoms**

**Keck B**, Stoehr R, Wach S, Rogler A, Nolte E, Hartmann A, Wullich B

**Urologe A. 2011;50(2):217-20.**

### **Originalarbeiten als Koautor**

- 1. A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.**

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, **Keck B**, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P.

**Oncotarget. 2018 Feb 19;9(19):15001-15014.**

- 2. Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.**

Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, **Keck B**, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P.

**Transl Oncol. 2018 Apr;11(2):467-476.**

- 3. Diagnostic potential of major and trace elements in the serum of bladder cancer patients.**

Wach S, Weigelt K, Michalke B, Lieb V, Stoehr R, **Keck B**, Hartmann A, Wullich B, Taubert H, Chaudhri A.

**J Trace Elem Med Biol. 2018 Mar;46:150-155.**

- 4. Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.**

van Kessel KEM, van der Keur KA, Dyrskjøt L, Algaba F, Welvaart NYC, Beukers W, Segersten U, **Keck B**, Maurer T, Simic T, Horstmann M, Grimm MO, Hermann GG, Mogensen K, Hartmann A, Harving N, Petersen AC, Jensen JB, Junker K, Boormans JL, Real FX, Malats N, Malmström PU, Ørntoft TF, Zwarthoff EC.

**Clin Cancer Res. 2018 Apr 1;24(7):1586-1593.**

- 5. Face-to-face vs. online peer support groups for prostate cancer: A cross-sectional comparison study.**

Huber J<sup>1</sup>, Muck T<sup>1</sup>, Maatz P<sup>1</sup>, **Keck B**<sup>2</sup>, Enders P<sup>3</sup>, Maatouk I<sup>4</sup>, Ihrig A<sup>5</sup>.

**J Cancer Surviv. 2018 Feb;12(1):1-9.**

6. **Immunohistochemical subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.**  
Sikic D, **Keck B**, Wach S, Taubert H, Wullich B, Goebell PJ, Kahlmeyer A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J; Bridge Consortium.  
**PLoS One. 2017 Jun 20;12(6)**
  
7. **Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.**  
Dyrskjøt L, Reinert T, Algaba F, Christensen E, Nieboer D, Hermann GG, Mogensen K, Beukers W, Marquez M, Segersten U, Høyer S, Ulhøi BP, Hartmann A, Stöhr R, Wach S, Nawroth R, Schwamborn K, Tulic C, Simic T, Junker K, Harving N, Petersen AC, Jensen JB, **Keck B**, Grimm MO, Horstmann M, Maurer T, Steyerberg EW, Zwarthoff EC, Real FX, Malats N, Malmström PU, Ørntoft TF.  
**Eur Urol. 2017 Sep;72(3):461-469.**
  
8. **Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort.**  
Vetterlein MW, Meyer CP, Leyh-Bannurah SR, Mayr R, Gierth M, Fritsche HM, Burger M, **Keck B**, Wullich B, Martini T, Bolenz C, Pycha A, Hanske J, Roghmann F, Noldus J, Bastian PJ, Gilfrich C, May M, Rink M, Chun FK, Dahlem R, Fisch M, Aziz A; PROMETRICS 2011 study group.  
**Clin Genitourin Cancer. 2017 Oct;15(5)**
  
9. **High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.**  
Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger D, Eckstein M, Stöhr R, Wach S, Wullich B, **Keck B**, Wirtz RM, Otto W.  
**Transl Oncol. 2017 Mar 22;10(3):340-345.**
  
10. **ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.** Breyer J, Otto W, Wirtz RM, Wullich B, **Keck B**, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium.. **Urol Int. 2016 Dec 17**
  
11. **Rhabdoid and Undifferentiated Phenotype in Renal Cell Carcinoma: Analysis of 32 Cases Indicating a Distinctive Common Pathway of Dedifferentiation Frequently Associated With SWI/SNF Complex Deficiency.** Agaimy A, Cheng L, Egevad L, Feyerabend B, Hes O, **Keck B**, Pizzolitto S, Sioletic S, Wullich

B, Hartmann A **Am J Surg Pathol.** 2016 Dec 14.

**12. The effect of an online support group on patients' treatment decisions for localized prostate cancer:**

**An online survey.**

Huber J, Maatz P, Muck T, **Keck B**, Friederich HC, Herzog W, Ihrig A.

**Urol Oncol.** 2016 Oct 31.

**13. Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study.**

Hager B, Kraywinkel K, **Keck B**, Katalinic A, Meyer M, Zeissig SR, Scheufele R, Wirth MP, Huber J.

**Prostate Cancer Prostatic Dis.** 2016 Sep 13

**14. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.**

Bertz S, Wach S, Taubert H, Merten R, Krause FS, Schick S, Ott OJ, Weigert E, Dworak O, Rödel C, Fietkau R, Wullich B, **Keck B**, Hartmann A.

**Virchows Arch.** 2016 Jul 8

**15. Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract.**

Agaimy A, Bertz S, Cheng L, Hes O, Junker K, **Keck B**, Lopez-Beltran A, Stöckle M, Wullich B, Hartman A.

**Virchows Arch.** 2016 Jun 23.

**16. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.**

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, Vang S, Reinert T, Hermann GG, Mogensen K, Thomsen MB, Nielsen MM, Marquez M, Segersten U, Aine M, Höglund M, Birkenkamp-Demtröder K, Fristrup N<sup>1</sup>, Borre M, Hartmann A, Stöhr R, Wach S, **Keck B**, Seitz AK, Nawroth R, Maurer T, Tulic C, Simic T, Junker K, Horstmann M, Harving N, Petersen AC, Calle ML, Steyerberg EW, Beukers W, van Kessel KE, Jensen JB, Pedersen JS, Malmström PU, Malats N, Real FX, Zwarthoff EC, Ørntoft TF, Dyrskjøt L.

**Cancer Cell.** 2016 Jun 16

**17. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.**

Leidinger P, Hart M, Backes C, Rheinheimer S, **Keck B**, Wullich B, Keller A, Meese E.

**Tumour Biol.** 2016 Jan 29.

**18. Results of Renal Transplantation on Alloplastic Arterial Grafts.**

Sagban TA, Regus S, Heller K, Jacobi J, Apel H, **Keck B**, Richterstetter M, Eckardt KU, Wullich B, Lang W.

**Urol Int.** 2016;96(2):157-63.

**19. Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis.**

Kunath F, Borgmann H, Blümle A, **Keck B**, Wullich B, Schmucker C, Sikic D, Roelle C, Schmidt S, Wahba A, Meerpohl JJ.

**BMJ Open. 2015 Nov 13;5(11):e008217.**

**20. Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia.**

Leidinger P, Keller A, Milchram L, Harz C, Hart M, Werth A, Lenhof HP, Weinhäusel A, **Keck B**, Wullich B, Ludwig N, Meese E.

**PLoS One. 2015 Jun 3;10(6):e0128235.**

**21. Piv12 expression is correlated with disease-specific and progression-free survival of chemotherapy-treated bladder cancer patients.**

Taubert H, Wach S, Jung R, Pugia M, **Keck B**, Bertz S, Nolte E, Stoehr R, Lehmann J, Ohlmann CH, Stöckle M, Wullich B, Hartmann A.

**Mol Med. 2015 May 13.**

**22. Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentapecta.**

Aziz A, Gierth M, Rink M, Schmid M, Chun FK, Dahlem R, Roghmann F, Palisaar RJ, Noldus J, Ellinger J, Müller SC, Pycha A, Martini T, Bolenz C, Moritz R, Herrmann E, **Keck B**, Wullich B, Mayr R, Fritsche HM, Burger M, Bastian PJ, Seitz C, Brookman-May S, Xylinas E, Shariat SF, Fisch M, May M; PROMETRICS 2011 Research Group.

**World J Urol. 2015 May 7**

**23. Integrated prostate cancer centers might cause an overutilization of radiotherapy for low-risk prostate cancer: A comparison of treatment trends in the United States and Germany from 2004 to 2011.**

Hager B, Kraywinkel K, **Keck B**, Katalinic A, Meyer M, Zeissig SR, Stabenow R, Froehner M, Huber J

**Radiother Oncol. 2015 Mar 11**

**24. Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder.**

Novotny V, Froehner M, May M, Protzel C, Hergenröther K, Rink M, Chun FK, Fisch M, Roghmann F, Palisaar RJ, Noldus J, Gierth M, Fritsche HM, Burger M, Sikic D, **Keck B**, Wullich B, Nuhn P, Buchner A, Stief CG, Vallo S, Bartsch G, Haferkamp A, Bastian PJ, Hakenberg OW, Propping S, Aziz A.

**World J Urol. 2015 Feb 8.**

**25. Treatment of nonmetastatic prostate cancer: a systematic review of interactive, personalized patient decision aids.**

Groeben C, Streuli JC, Krones T, **Keck B**, Wirth MP, Huber J.

**Urologe A. 2014 Jun;53(6):854-64.**

**26. Association of tissue mRNA and serum antigen levels of members of the urokinase-type plasminogen activator system with clinical and prognostic parameters in prostate cancer.**

Al-Janabi O, Taubert H, Lohse-Fischer A, Fröhner M, Wach S, Stöhr R, **Keck B**, Burger M, Wieland W, Erdmann K, Wirth MP, Wullich B, Baretton G, Magdolen V, Kotzsch M, Füssel S.

**Biomed Res Int. 2014;2014:972587.**

**27. MicroRNA profiles classify papillary renal cell carcinoma subtypes.**

Wach S, Nolte E, Theil A, Stöhr C, T Rau T, Hartmann A, Ekici A, **Keck B**, Taubert H, Wullich B.

**Brit J Cancer. 2013;6;109(3):714-22.**

**28. Is gender becoming relevant in uro-oncological research? A bibliographical analysis.**

Kunath F, **Keck B**, Bertz S, Brookman-May S, May M, Vergo D, Hartmann A, Riedmiller H, Wullich B, Burger M.

**World J Urol. 2013 2013;31(5):1065-72.**

**29. Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review.**

Kunath F, **Keck B**, Rücker G, Motschall E, Wullich B, Antes G, Meerpohl JJ.

**BMC Cancer. 2013;19;13:131.**

**30. MRI-guided core biopsy of the prostate in the supine position-introduction of a simplified technique using large-bore magnet systems.**

Schwab SA, Kuefner MA, Adamietz B, Engelhard K, **Keck B**, Kunath F, Wach S, Wullich B, Uder M, Engehausen DG.

**Eur Radiol. 2013;23(5):1415-9.**

**31. Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme.**

Heidenreich A, Scholz HJ, Rogenhofer S, Arsov C, Retz M, Müller SC, Albers P, J, Wirth M, Steiner U, Miller K, Heinrich E, Trojan L, Volkmer B, Honecker F, Bokemeyer C, **Keck B**, Otremba B, Ecstein-Fraisse E, Pfister D.

**Eur Urol. 2013;63(6):977-82.**

**32. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: A systematic review**

Frank Kunath, **Bastian Keck**, Gerd Antes, Bernd Wullich and Joerg J Meerpohl

**BMC Medicine. 2012;28;10(1):96.**

**33. Identification of ZNF217, hnRNP-K, VEGF-A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma.**

Szczyrba J, Nolte E, Hart M, Döll C, Wach S, Taubert H, **Keck B**, Kremmer E, Stöhr R, Hartmann A, Wieland W, Wullich B, Grässer FA

**Int J Cancer. 2013; 15;132(4):775-84.**

**34. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening.**

Wach S, Nolte E, Szczyrba J, Stöhr R, Hartmann A, Ørntoft T, Dyrskjøt L, Eltze E, Wieland W, **Keck B**, Ekici AB, Grässer F, Wullich B.

**Int J Cancer. 2012;1;130(3):611-21.**

**35. Do urology journals enforce trial registration? A cross-sectional study of published trials.**

Kunath F, Grobe HR, **Keck B**, Rücker G, Wullich B, Antes G, Meerpohl JJ

**BMJ Open. 2011;6;1(2):e000430**

**36. Towards discovering the blood-born miRNome of human diseases**

A Keller, P Leidinger, A Bauer, A ElSharawi, J Haas, A Borries, A Wendschlag, N Giese, C Tjaden, S Nikolaus, K Ruprecht, H Huwer, J Huebers, G Jacobsen, H Dommisch, A Schaefer, S Hoffmann, B Wullich, **B Keck**, N Graf, J Reichrath, SU Jager, P Staehler, J Lange, C Staehler, M Beier, M Scheffler,



MW Buechler, JWischhusen, SFM Haeusler, J Dietl, J Mueller-Quernheim, C Backes, HP Lenhof, S Schreiber, HA Katus, W Rottbauer, B Meder, A Franke, JD Hoheisel, E Meese

**Nature Methods. 2011;4;8(10):841-3**

**37. Mutational activation of FGFR3 is not involved in the development of prostate cancer**

Stella Koufou, Jens-Claudio Lunz, Albert Borchardt, **Bastian Keck**, Burkhard Kneitz, Nadine T. Gaisa, Christian Hafner, Christian Giedl, Tilman T. Rau, Anja Rogler, Arndt Hartmann, Robert Stoehr

**Pathobiology. 2010;77:249–252**

**38. “Identifying the affected hemisphere by <sup>1</sup>H-MR spectroscopy in patients with temporal lobe epilepsy and no pathological findings in high resolution MRI”**

T. Hammen, F. Kerling, M. Schwarz, A. Stadlbauer, O. Ganslandt, **B. Keck**, B. Tomandl, A.Dörfler and H. Stefan

**Eur J Neurol. 2006 May;13(5):482-90.**

**B: Publikationen von Case Reports**

**1. Clinical course of plasmacytoid urothelial carcinoma of the upper urinary tract: A case report.**

**Keck B**, Giedl J, Kunath F, Goebell PJ, Engehausen DG, Hartmann A, Wullich B

**Urol Int. 2012;89(1):120-2.**

**2. Sonographic diagnosis of a posttraumatic arteriocavernosal fistula resulting in high-flow priapism.**

**Keck B**, Lotter G, Wieland WF, Wullich B, Uder M, Engehausen DG, Fritsche HM.

**J Clin Ultrasound 2012;40(1):60-2.**

**3. Diagnostic challenge of atypical colorectal metastasis to the renal pelvis**

**Keck B**, Rau T, Krause FS, Walter B, Goebell P, Hartmann A, Wullich

**Int J Colorectal Dis. 2011 Apr;26(4):523-4.**

4. **Das Plasmazytoide Urothelkarzinom – 5 Fallberichte einer seltenen Variante des Urothelkarzinoms**  
**B. Keck, R. Stöhr, P.J. Goebell, H.M. Fritsche, B. Wullich, A. Hartmann**  
**Pathologe. 2008; 29(5):379-82**

## **C: Publikationen von Reviews als Erst- oder Koautor**

1. Kommentar zu  
**Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study.** Geijsen ED, de Reijke TM, Koning CC, Zum Vörde Sive Vörding PJ, de la Rosette JJ, Rasch CR, van Os RM, Crezee J.  
**J Urol. 2015 Nov;194(5):1202-8.**  
**Keck B.**  
**Aktuelle Urologie 2016**
2. **Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects.**  
Lieb V, Rink M, Sikic D, **Keck B.**  
**Urologe A. 2016 May 4.**
3. **Side effect management of tyrosine kinase inhibitors in urology : Hypertension.**  
Sikic D, Meidenbauer N, Lieb V, **Keck B.**  
**Urologe A. 2016 May 4.**
4. **Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism.**  
Sikic D, Lüdecke G, Lieb V, **Keck B.**  
**Urologe A. 2016 May;55(5):648-52.**
5. **Operative therapy of spinal metastases from urological tumors**  
Richter RH, Hammon M, Uder M, Huber J, Goebell PJ, Kunath F, Wullich B, **Keck B.**  
**Urologe A. 2016 Feb;55(2):232-40.**
6. **Vertebral metastases of urogenital carcinomas : Diagnosis and conservative therapy.**

**Keck B, Hammon M, Uder M, Huber J, Goebell PJ, Kunath F, Wullich B, Richter RH.**

**Urologe A. 2015 Oct 10.**

**7. Bladder cancer in focus: Update 2012 of the German Bladder Cancer Association.**

**Keck B, Merseburger AS, Stöhr R, Füssel S, Hoffmann MJ, Schmid S, Olbert P, Hartmann A, Nawroth R.**

**Urologe A. 2013;52(3):373-7**

**8. Stellenwert von Biomarkern in der Urologie**

**P.J. Goebell, B. Keck, S. Wach, B. Wullich**

**Urologe A. 2010; 49:547–559**

**9. Kommentar zu**

**„Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis“ Mitra et al.,**

**Urol Oncol 23(2014) 117-127**

**Keck B**

**Uro-Scan 2014; 1**

**10. Kommentar zu**

**„Comparative survival following different treatment modalities for stage T2 bladder cancer in octogenarians“ Trulson et al., World J Urol (2014) 32:425-429**

**Keck B.**

**Uro-Scan 2014;2**